Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct 11;5(10):4093-114.
doi: 10.3390/nu5104093.

Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD)

Affiliations
Review

Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD)

Beth A Conlon et al. Nutrients. .

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an emerging global health concern. It is the most common form of chronic liver disease in Western countries, affecting both adults and children. NAFLD encompasses a broad spectrum of fatty liver disease, ranging from simple steatosis (NAFL) to nonalcoholic steatohepatitis (NASH), and is strongly associated with obesity, insulin resistance, and dyslipidemia. First-line therapy for NAFLD includes weight loss achieved through diet and physical activity. However, there is a lack of evidenced-based dietary recommendations. The American Diabetes Association's (ADA) recommendations that aim to reduce the risk of diabetes and cardiovascular disease may also be applicable to the NAFLD population. The objectives of this review are to: (1) provide an overview of NAFLD in the context of insulin resistance, and (2) provide a rationale for applying relevant aspects of the ADA recommendations to the nutritional management of NAFLD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Nonalcoholic Fatty Liver Disease (NAFLD) is histologically categorized into Nonalcoholic Fatty Liver (NAFL) and Nonalcoholic Steatohepatitis (NASH) [1,7,11].
Figure 2
Figure 2
The two-hit hypothesis of NAFLD progression [34]. Reproduced from [35] (Copyright © 2008 Novo et al.; licensee BioMed Central Ltd.).

References

    1. Bellentani S., Scaglioni F., Marino M., Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 2010;28:155–161. doi: 10.1159/000282080. - DOI - PubMed
    1. Vernon G., Baranova A., Younossi Z.M. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011;34:274–285. doi: 10.1111/j.1365-2036.2011.04724.x. - DOI - PubMed
    1. Rinella M.E. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make nash the deadlier disease? Hepatology. 2011;54:1118–1120. doi: 10.1002/hep.24634. - DOI - PubMed
    1. Targher G., Bertolini L., Padovani R., Rodella S., Tessari R., Zenari L., Day C., Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among tyep 2 diabetic patients. Diabetes Care. 2007;30:1212–1218. doi: 10.2337/dc06-2247. - DOI - PubMed
    1. Leite N.C., Salles G.F., Araujo A.L., Villela-Nogueira C.A., Cardoso C.R. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113–119. doi: 10.1111/j.1478-3231.2008.01718.x. - DOI - PubMed

MeSH terms

LinkOut - more resources